Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ACP3 | P15309 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8870718 | 1.00 | KMT2A (0.54) | KMT2AMEN1HPGDL3MBTL1TSHR | |
| SCHEMBL2150915 | 0.81 | MEN1 (0.52) | KMT2AMEN1HPGDL3MBTL1TSHR | |
| SCHEMBL15617613 | 0.81 | MEN1 (0.52) | KMT2AMEN1HPGDL3MBTL1TSHR | |
| SCHEMBL254876 | 0.80 | TSHR (0.61) | KMT2AMEN1HPGDL3MBTL1TSHR | |
| SCHEMBL12395375 | 0.80 | TSHR (0.52) | KMT2AMEN1HPGDL3MBTL1TSHR | |
| SCHEMBL741878 | 0.80 | TSHR (0.52) | KMT2AMEN1HPGDL3MBTL1TSHR | |
| SCHEMBL5757472 | 0.80 | TSHR (0.52) | KMT2AMEN1HPGDL3MBTL1TSHR | |
| SCHEMBL7734153 | 0.80 | TSHR (0.52) | KMT2AMEN1HPGDL3MBTL1TSHR | |
| SCHEMBL28757603 | 0.80 | TSHR (0.52) | KMT2AMEN1HPGDL3MBTL1TSHR | |
| SCHEMBL171673 | 0.80 | KMT2A (0.53) | KMT2AMEN1HPGDL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4499026-A | Nucleophilic substitution process | ETHYL CORPORATION (US) | 1985-02-12 | — | — | US | claimed |
| CN-107721804-B | Method for preparing o-xylene through 3-nitro-o-xylene | 绍兴贝斯美化工股份有限公司 | 2020-09-18 | — | — | CN | disclosed |
| US-7619095-B2 | Process for the preparation of indolone derivative | ALEMBIC LIMITED (IN) | 2009-11-17 | — | — | US | disclosed |
| EP-1848691-B1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LTD (IN) | 2009-11-11 | — | — | EP | disclosed |
| US-20080262244-A1 | Process for the Preparation of Indolone Derivative | ALEMBIC LIMITED (IN) | 2008-10-23 | — | — | US | disclosed |
| EP-1848691-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | Alembic Limited (IN) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006123356-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LIMITED (IN) | 2006-11-23 | — | — | WO | disclosed |
| US-7026357-B2 | Diphenylurea compounds | LES LABORATOIRES SERVIER (FR) | 2006-04-11 | — | — | US | disclosed |
| CN-1241916-C | Novel acardite compound, its preparation method and medicinal composition containing said compound | SERVIER LAB (FR) | 2006-02-15 | — | — | CN | disclosed |
| EP-1170288-B9 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | SERVIER LAB (FR) | 2005-01-26 | — | — | EP | disclosed |
| US-20020025965-A1 | Antiserotonine agents | ADIR ET COMPAGNIE (FR) | 2002-02-28 | — | — | US | disclosed |
| EP-1170288-A2 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
| US-5610144-A | CHOLECYSTOKININ OR GASTRIN ANTAGONISTS; NERVOUS SYSTEM AND GASTROINTESTINAL DISORDERS | RHONE-POULENC RORER S.A. (FR) | 1997-03-11 | — | — | US | disclosed |
| US-5475106-A | Agonist for cholecystokinin and gastrin receptors; nervous system, gastrointestinal disorders | RHONE-POULENC RORER S.A. (FR) | 1995-12-12 | — | — | US | disclosed |
| US-5382590-A | Gastrointestinal disorders and nervous system disorders | RHONE-POULENC RORER S.A. (FR) | 1995-01-17 | — | — | US | disclosed |
| EP-0078709-B1 | PREPARATION OF NITROARALKYL CYANIDES AND DERIVATIVES THEREOF | ETHYL CORPORATION (US) | 1986-10-01 | — | — | EP | disclosed |
| US-4499026-A | Nucleophilic substitution process | ETHYL CORPORATION (US) | 1985-02-12 | — | — | US | disclosed |
| US-4479904-A | Reduction of nitroaromatic compounds | ETHYL CORPORATION (US) | 1984-10-30 | — | — | US | disclosed |
| EP-0078709-A2 | Preparation of nitroaralkyl cyanides and derivatives thereof | ETHYL CORPORATION (US) | 1983-05-11 | — | — | EP | disclosed |
| US-4323388-A | Cyanoalkyl-phenylureas having selective herbicidal activity | CIBA-GEIGY CORPORATION (US) | 1982-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025965-A1 | Antiserotonine agents | HTR2C, HTR3C, HTR3A | KMT2A 1009/4885MEN1 3550/4885HPGD 2727/4885 |
| US-20080262244-A1 | Process for the Preparation of Indolone Derivative | HTR3C, HTR3B, HTR1B | KMT2A 1799/4885MEN1 2586/4885HPGD 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.